VolitionRx's Nu.Q® NETs Platform Advances Toward Sepsis Market
Event summary
- VolitionRx has amassed significant clinical and scientific evidence supporting its Nu.Q® NETs platform for sepsis management.
- The company is in active discussions with large diagnostic firms to accelerate commercialization, targeting a $3.8 billion addressable market.
- Nu.Q® H3.1 accurately distinguishes sepsis from non-infectious inflammation and correlates with disease severity and mortality outcomes.
- Peer-reviewed studies confirm the platform's potential as a 'game changer' in sepsis management.
The big picture
VolitionRx's progress with Nu.Q® NETs underscores the growing emphasis on early detection and personalized treatment in critical care. The platform's ability to provide additional prognostic insights beyond standard organ failure scores positions it as a potential disruptor in sepsis management, a market ripe for innovation given the high mortality rates and healthcare costs associated with the condition.
What we're watching
- Commercialization Pace
- How quickly VolitionRx can secure partnerships and regulatory approvals to bring Nu.Q® NETs to market.
- Market Adoption
- Whether hospitals will integrate the test into sepsis management protocols, given its prognostic utility.
- Competitive Positioning
- The extent to which Nu.Q® NETs can differentiate itself in a crowded sepsis diagnostics space.
Related topics